group L

PreclinicalSmall molecule

SSeoul National University Hospital

group L is one of 9 small molecule programs targeting Sore Throat. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sore ThroatRecruiting

Tracheal IntubationUnknown status

Sore ThroatPreclinical

Recruiting

Tracheal IntubationPreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Tracheal Intubation

#DrugCompanyPhaseTrials

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Noradrenaline

IInstitute of Liver and Biliary Sciences, India

Phase 3

1 3

Olinvyk

TTrevena Inc.

Preclinical

1 4

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Tegileridine

XXin Chen

Preclinical

1 6

group L

SSeoul National University Hospital

Preclinical

1 7

Magnesium Sulfate- Fentanyl

NNational Cancer Institute, Egypt

Preclinical

1 8

Lidocaine /kg

WWest China Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Sore Throat

NCT07780760

Clinical

Trials by Indication[1]

Post Operative Pain1 trial

The Effect of Lidocaine Patch for Postoperative Pain

Completed·BBON WOOK KOO·Phase 4·NCT04754451·32 enrolled

Tracheal Intubation1 trial

Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation

Unknown status·SSeoul National University Hospital·N/A·NCT01737437·80 enrolled

Sore Throat1 trial

Effect of Preoprative Nebulized Dexmedetomidine Compared to Nebulized Lidocaine in Attenuating Sore Throat Following Tonsillectomy In Childern. A Prospective, Randomized, Double-Blinded Trial.

Recruiting·FFayoum University Hospital·Preclinical·NCT07780760·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for group L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — group L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for group L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

group L

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Post Operative Pain1 trial

Tracheal Intubation1 trial

Sore Throat1 trial

References

Drug Info

Quick Facts

Related News